Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study.
BACKGROUND
A retrospective, registry-based analysis to assess the outcomes of metastatic renal cell cancer (mRCC) patients treated with sunitinib and sorafenib who developed dermatologic adverse events was performed.


METHODS
Data on mRCC patients treated with sunitinib or sorafenib were obtained from the Czech Clinical Registry of Renal Cell Cancer Patients. Outcomes of patients who developed hand-foot syndrome (HFS) of any grade and/or grade 3/4 rash during the treatment were compared with patients without HFS and no, mild, or moderate rash.


RESULTS
The cohort included 705 patients treated with sunitinib and 365 patients treated with sorafenib. For sunitinib, the median overall survival (OS) was 43.0 months versus 31.0 months (P = 0.027) and median progression-free survival (PFS) 20.8 months versus 11.1 months (P = 0.007) for patients with versus without dermatologic toxicity, respectively. For sorafenib, the median OS and PFS were 27.9 and 24.6 months (P = 0.244), and 12.2 and 8.8 months (P = 0.050), respectively. In multivariable Cox regression, the skin toxicity was significantly associated with longer OS in the sunitinib cohort.


CONCLUSIONS
The presence of skin toxicity is associated with improved OS and PFS in patients with mRCC treated with sunitinib.
Masaryk Memorial Cancer Institute of Oncology, Brno, Czech Republic.
A
A
Poprach
Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic.
T
T
Pavlik
Department of Oncology, Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic.
B
B
Melichar
Vanderbilt University Medical Center, Nashville, USA.
I
I
Puzanov
Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic.
L
L
Dusek
Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic.
Z
Z
Bortlicek
Masaryk Memorial Cancer Institute of Oncology, Brno, Czech Republic.
R
R
Vyzula
Department of Oncology and 1st Faculty of Medicine, Thomayer University Hospital and Charles University, Prague, Czech Republic.
J
J
Abrahamova
Department of Oncology and 1st Faculty of Medicine, Thomayer University Hospital and Charles University, Prague, Czech Republic. Electronic address: tomas.buchler@ftn.cz.
T
T
Buchler
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000401:mortality; D018572:Disease-Free Survival; D005076:Exanthema / Q000139:chemically induced; D005260:Female; D060831:Hand-Foot Syndrome; D006801:Humans; D007211:Indoles / Q000009:adverse effects* / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009536:Niacinamide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D011758:Pyrroles / Q000009:adverse effects* / Q000627:therapeutic use; D012042:Registries; D012189:Retrospective Studies; D012867:Skin / Q000187:drug effects*; D000077157:Sorafenib; D000077210:Sunitinib; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D007211:Indoles; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011758:Pyrroles; D009536:Niacinamide; D000077157:Sorafenib; D000077210:Sunitinib